Abstract Body

Background

The use of integrase strand transfer inhibitors (INSTI) is associated with weight gain, but the underlying mechanisms remain unclear. This study aims to compare the plasma proteomic alterations in people with HIV (PWH) who experienced different weight trends after using INSTI, and to identify critical factors in INSTI-induced weight gain.

Methods

Three cohorts of PWH using INSTI in PUMCH were included, (1) PWH switched from Non-Nucleoside Reverse Transcrіpatse Inhibitors (NNRTI)- to INSTI-based regimen with >5% weight gain at 12 months (N=22); (2) PWH switched from NNRTI- to INSTI-based regimen with no apparent weight gain at 12 months (N=18); and (3) Treatment-naïve PWH initiating INSTI-based regimen with >5% weight gain at 12 months (N=27). All participants had plasma collected at baseline and 12-month of INSTI-based therapy. Quantitative proteomics analysis was performed, and the limma package was used to identify differentially expressed proteins (DEPs) in INSTI-naive samples. These DEPs were defined by the criteria of |log₂FC| > 1 and adjusted P-value < 0.1. To evaluate the differences in DEPs expression across multiple time points within groups, a paired t-test was employed.

Results

We identified seven significantly DEPs in INSTI-naïve patients, including IGHV4-34, PFKM, AARS1, PPP2R1A, IGLV2-11, FAH, and CLPP. Further comparison with the switching group showed that IGHV4-34 and CLPP exhibited the same expression trend in those with significant weight gains, whereas an inverse expression trend was observed in non-weight gainers. Notably, CLPP was markedly upregulated in INSTI-naïve weight gainers (p = 0.002); a similar upregulation pattern was also detected in NNRTI-experienced patients who gained weight after switching to INSTI (p = 0.012). However, this CLPP upregulation pattern was absent in patients who maintained weight stability following INSTI switch (p = 0.32).

Conclusions

We identified a proteomic signature for INSTI-induced weight gain, with changes in mitochondrial protein processing and immune regulation. CLPP’s consistent upregulation with weight gain indicates its role as a biomarker for INSTI-associated metabolic changes, and further mechanistic insights into this effect.

Table or Figure